One platform to run faster, more inclusive trials, together

Inato unites sponsors, research sites, and patients through one AI-powered platform, expanding access, increasing efficiency, and bringing life-changing treatments to more communities around the world.

Built for global impact. Designed for local access.

Inato is the only platform that brings sponsors and sites together to unlock access to clinical trials, faster and more equitably.

25+

Activate diverse, high-performing sites faster with better planning, selection, and enrollment, all in one place.

Win more trial opportunities matched to your capabilities, with tools that reduce burden and boost performance.

Compliance you
can count on.

Our global presence

50+

Countries

6,000+

Sites

25+

Sponsors

Trusted by today’s clinical research leaders

We co-develop our technology with forward-thinking pharma and site leaders to ensure every trial is faster, more efficient, and more inclusive.

One intelligent platform to run better trials

Optimize across your portfolio with insights from sites who can deliver on your trials.

Charts showing US patient population demographics and barriers to recruitment with comparison between US and Ex-US, plus treatment options impact and site comments on trial visit challenges.

Pie chart showing US patient population by race: Hispanic 50%, White 26%, Black 19%, Asian 3%, Other 2%.

Leverage AI to find the right mix of qualified, motivated sites based on actual capabilities and patient access.

Comparison cards for two clinical research sites: Abbott Northwestern Hospital led by Oscar G. Guttierez in Vineland, NJ, with 20 patients IVC, 6 PI trials in NSCLC, and 100% requirements met; and Applied Clinical Research led by Alexandra Brown, M.D. in Miami, FL, with 3 patients IVC, 4 trials in NSCLC, and 80% requirements met.

Chat interface suggesting three best clinical trial sites: Abbott Northwestern Hospital, Applied Clinical Research, and Clinical Research, with explanation of diversity and speed benefits.

Reduce site burden and accelerate patient enrollment by using AI to automate chart review and pre-screening.

Patient pre-screening table for Phase 3 Brinkamab severe asthma study showing six patients with their prescreening percentages and status: three to screen with 80-92%, two failed with 20-30%, and one to review at 10%.

Line chart showing a steady increase in patients pre-screened from December 29 to March 13, reaching a total of 35 patients.

Text highlighting top criteria for ineligibility as any other active disease or condition interfering with asthma assessment, with 31 patients excluded.